Bristol-Myers Squibb Co

NYSE:BMYUnited States

Bristol Myers Squibb to Participate in Citi's 2024 Global Healthcare Conference
PRINCETON, N.J.--(BUSINESS WIRE)--November 26, 2024--
Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in Citi's 2024 Global Healthcare Conference.

06:06 AM EST, 11/25/2024 (MT Newswires) -- Bristol-Myers Squibb (BMY) has an average rating of hold and mean price target of $58.90, according to analysts polled by FactSet. (MT Newswires covers equity, commodity and economic research from major ban...

Ed Lin

One of the largest U.S. pensions recently made a big bet on two tech stocks and a healthcare company, slashing a position in a drug maker.

The State of Michigan Retirement Systems doubled a stake in Palantir Technologies, bought up Intel stock, and increased a stake in CVS Health, while it significantly reduced an investment in Bristol Myers Squibb. The pension reported the stock trades, among others, in a form it filed with the Securities and Exchange Commission.

Bristol Myers Squibb is inspired by a single vision--transforming patients' lives through science. The goal of the company's cancer research is to deliver medicines that offer each patient a better, healthier life and to make cure a possibility. Building on a legacy across a broad range of cancers that have changed survival expectations for many, Bristol Myers Squibb researchers are exploring new frontiers in personalized medicine, and through innovative digital platforms, are turning data into insights that sharpen their focus. Deep understanding of causal human biology, cutting-edge capabilities and differentiated research platforms uniquely position the company to approach cancer from every angle.